A carregar...
Phase I trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma
BACKGROUND: Simultaneous inhibition of the vascular epithelial growth factor (VEGF) and the mammalian target of rapamycin (mTOR) pathway may improve treatment response in advanced renal cell carcinoma (RCC). Everolimus, an oral mTOR inhibitor, and sunitinib, an oral tyrosine kinase inhibitor (TKI) t...
Na minha lista:
| Main Authors: | , , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
2011
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3609026/ https://ncbi.nlm.nih.gov/pubmed/21898375 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.26429 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|